Prag-1
Lymphopenia
Second Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Lymphopenia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Angiotensin-(1-7) Tarix Pharmaceuticals | Phase 2 | CCC |
RAMIFENTANYL Guizhi Du | D | |
Sevoflurane Guizhi Du | D | |
PROPOFOL Guizhi Du | D |
Same molecule, other indications
Prag-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →